153 related articles for article (PubMed ID: 36518085)
1. Plasma phosphorylated tau181 predicts cognitive and functional decline.
Tropea TF; Waligorska T; Xie SX; Nasrallah IM; Cousins KAQ; Trojanowski JQ; Grossman M; Irwin DJ; Weintraub D; Lee EB; Wolk DA; Chen-Plotkin AS; Shaw LM;
Ann Clin Transl Neurol; 2023 Jan; 10(1):18-31. PubMed ID: 36518085
[TBL] [Abstract][Full Text] [Related]
2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
[TBL] [Abstract][Full Text] [Related]
4. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
[TBL] [Abstract][Full Text] [Related]
5. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression.
Tsiknia AA; Edland SD; Sundermann EE; Reas ET; Brewer JB; Galasko D; Banks SJ;
Mol Psychiatry; 2022 Oct; 27(10):4314-4322. PubMed ID: 35768637
[TBL] [Abstract][Full Text] [Related]
7. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
[TBL] [Abstract][Full Text] [Related]
8. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
9. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Janelidze S; Mattsson N; Palmqvist S; Smith R; Beach TG; Serrano GE; Chai X; Proctor NK; Eichenlaub U; Zetterberg H; Blennow K; Reiman EM; Stomrud E; Dage JL; Hansson O
Nat Med; 2020 Mar; 26(3):379-386. PubMed ID: 32123385
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
[TBL] [Abstract][Full Text] [Related]
12. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
Huang Y; Li Y; Xie F; Guo Q
CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
[TBL] [Abstract][Full Text] [Related]
13. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
14. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
Lantero Rodriguez J; Karikari TK; Suárez-Calvet M; Troakes C; King A; Emersic A; Aarsland D; Hye A; Zetterberg H; Blennow K; Ashton NJ
Acta Neuropathol; 2020 Sep; 140(3):267-278. PubMed ID: 32720099
[TBL] [Abstract][Full Text] [Related]
15. Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.
Xiao Z; Wu X; Wu W; Yi J; Liang X; Ding S; Zheng L; Luo J; Gu H; Zhao Q; Xu H; Ding D
Alzheimers Res Ther; 2021 Jul; 13(1):123. PubMed ID: 34225797
[TBL] [Abstract][Full Text] [Related]
16. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
Tieu MV; Choi SH; Le HTN; Cho S
Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
[TBL] [Abstract][Full Text] [Related]
17. Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.
Lehmann S; Schraen-Maschke S; Vidal JS; Delaby C; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Hanon O
J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):411-419. PubMed ID: 37012068
[TBL] [Abstract][Full Text] [Related]
18. Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer's disease.
Wilson EN; Young CB; Ramos Benitez J; Swarovski MS; Feinstein I; Vandijck M; Le Guen Y; Kasireddy NM; Shahid M; Corso NK; Wang Q; Kennedy G; Trelle AN; Lind B; Channappa D; Belnap M; Ramirez V; Skylar-Scott I; Younes K; Yutsis MV; Le Bastard N; Quinn JF; van Dyck CH; Nairn A; Fredericks CA; Tian L; Kerchner GA; Montine TJ; Sha SJ; Davidzon G; Henderson VW; Longo FM; Greicius MD; Wagner AD; Wyss-Coray T; Poston KL; Mormino EC; Andreasson KI
Alzheimers Res Ther; 2022 Nov; 14(1):172. PubMed ID: 36371232
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
20. Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change.
Smirnov DS; Ashton NJ; Blennow K; Zetterberg H; Simrén J; Lantero-Rodriguez J; Karikari TK; Hiniker A; Rissman RA; Salmon DP; Galasko D
Acta Neuropathol; 2022 Apr; 143(4):487-503. PubMed ID: 35195758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
